Condition
Ewing's Sarcoma Family of Tumors
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Completed2
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT00560235Phase 1CompletedPrimary
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
NCT01518413Phase 1Completed
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
NCT01112800Withdrawn
Markers of Anthracycline-Related Cardiac Muscle Injury
Showing all 3 trials